Log In
Print
BCIQ
Print
Print this Print this
 

Extended Release Carbinoxamine Oral Suspension, Karbinal ER carbinoxamine maleate

  Manage Alerts
Collapse Summary General Information
Company Tris Pharma Inc.
DescriptionOral antihistamine is formulated with Tris' OralXR+ technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationAllergy
Indication DetailsTreat allergies in children >=2 years of age
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$20.0M

0

$20.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today